Approval number: HZ200302

Indications Liladomide is mainly used to treat patients with transfusion-dependent anemia caused by myelodysplastic syndrome with 5q deletion cytogenetic abnormality.

Dosage and Administration Liladomide is an oral capsule with 5mg and 10mg specifications. The recommended initial dose of leradotamide is 10mg per day. The dosage of loratadine can be adjusted according to the patient's clinical symptoms and laboratory test results. The FDA of the United States recommends that patients who receive LODOMINE should have a whole blood cell count once a week in the first 8 weeks of treatment, and then check it once a month. Some patients may also need to supplement blood products and/or growth factors.

Medication reminds doctors to provide medication guidance to patients every time they prescribe loratadine. Doctors or pharmacists should take this opportunity to explain the possible risks of loratadine to patients. It is best for patients who are ready to take medicine to take two different effective contraceptive measures at the same time. Female patients who are going to take Liladomide should sign an informed consent form under the guidance of a doctor to show that they already know the importance of contraception when taking Liladomide. In addition, all female patients who are likely to get pregnant need to have two pregnancy tests before taking the medicine (one is scheduled for 10 ~ 14 days before taking the medicine, and the other is scheduled within 24 hours before taking the medicine), and only those who have negative results from the two pregnancy tests can formally take lyddamide.

The generic names are rellidomide and REVANA.

Indications are applicable to multiple myeloma and myelodysplastic syndrome.

Usage and dosage Multiple myeloma takes 25mg daily; Myelopathy syndrome 10 mg/day.

The pinnacle of Peru